Andera Partners is a private equity firm that focuses on supporting companies and their managers in achieving strong, sustainable growth across several key areas. Their investment strategies include life sciences, green innovative infrastructures, and European SMEs and mid-caps through growth, buyout, and sponsorless mezzanine financing. The firm emphasizes innovation and sustainability as core to its approach, acting as a sparring partner for entrepreneurs to drive organic and external growth, international development, and corporate governance.
58% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-a (67% of deals). Average disclosed round size is $63.9M (across 12 rounds with reported amounts).
Portfolio
12
Fund Size
$5.1B
Top Stage
Series A
Last 12 Mo
3
Team
Cory Steffek
Partner
Aneta Sottil
Director
Raphael Wisniewski
Investor
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Alveus Therapeutics Inc | Series A | $160M | Jan 2026 |
 Spiro Medical, Inc. | Series A | $67M | Jan 2026 |
 TargED Biopharmaceuticals | Series A | $21.5M | Dec 2025 |
 EG 427 | Series B | $27M | Feb 2025 |
| EExciva GmbH | Series B | $59M | Jan 2025 |
 Bioptimus | Series A | $41M | Jan 2025 |
| DDualyx | Series A | $44M | May 2023 |
| BBioVentrix, Inc. | Series A | $48.5M | Apr 2023 |
 Mineralys Therapeutics, Inc. | Series B | $118M | Jun 2022 |
 Evommune, Inc. | Series A | $83M | Sep 2021 |
| TT-knife GmbH | Series A | $66M | Aug 2020 |
| HHighLife SAS | Series B | $32M | Jan 2019 |
Top Co-Investors
Last updated: 5 March 2026